Community-Driven Psilocybin Therapy Study in New Mexico

Community Engagement in Psilocybin Therapy Research

A recent study in New Mexico highlights the importance of community engagement in developing psilocybin-assisted therapy for post-traumatic stress disorder (PTSD). This initiative, led by the University of New Mexico (UNM) and its partners, integrates local stakeholder input into the design and implementation of Group Psilocybin-Assisted Therapy (GPAT). The study's community-informed approach ensures that the therapy is accessible to populations facing structural barriers, such as veterans and women survivors of sexual violence.

The research aligns with New Mexico's Therapeutic Psilocybin Program, utilizing state-regulated whole psilocybin mushrooms to focus on access and equity. This approach is part of a broader strategy to build trust and ensure that those most impacted by PTSD have a voice in the treatment development process.

Mechanism and Context of the Study

The study employs a pragmatic, open-label, hybrid feasibility-implementation model. It includes six groups of six participants each, who will undergo two sessions using psilocybin mushroom-infused chocolates containing 20 mg and 30 mg of psilocybin. These sessions are complemented by both group and individual therapy, guided by peer facilitators who share affinities with the participant groups.

Outcomes will be measured using standard PTSD assessment tools, such as the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) and the PTSD Checklist for DSM-5 (PCL-5). An extended integration model is also part of the study, providing long-term support to participants beyond the clinical trial.

Policy and Research Implications

This study's design reflects a growing recognition of the need for inclusive research practices in psychedelic therapy. By involving community stakeholders from the outset, the research aims to create a model that is not only effective but also trusted by the communities it serves. This approach could inform future policy decisions on psychedelic therapy implementation, particularly in regions prioritizing equity and access.

The collaboration with the University of California, Berkeley Collaborative for the Economics of Psychedelics (CEP) adds an economic dimension to the study. By conducting a prospective micro-costing analysis, the study will provide insights into the costs associated with delivering a comprehensive and safe model of care, which is crucial for scaling these therapies effectively.

Risks and Unknowns

While the study is promising, it also faces challenges. The use of whole psilocybin mushrooms, though aligned with state regulations, may introduce variability in psilocybin content compared to synthesized alternatives. This could affect the consistency of therapeutic outcomes. Additionally, the integration of community feedback, while beneficial, may also complicate the standardization of protocols across different sites and populations.

There are also broader concerns about the scalability of such community-driven models. While they are effective in ensuring local relevance and trust, replicating these models in diverse settings may require significant adaptation and resources.

Looking Forward

The New Mexico study represents a significant step forward in the integration of community engagement into psychedelic research. As the field of psychedelic-assisted therapy continues to evolve, such models could serve as blueprints for future studies, particularly those aiming to address health disparities. The economic analysis component will provide valuable data on the feasibility of scaling these therapies, offering insights that could shape the future landscape of psychedelic treatment.

Ultimately, the success of this study could influence how psychedelic therapies are developed and implemented globally, highlighting the importance of community involvement in creating equitable and effective mental health interventions.